Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation
Highlights • Endocannabinoid augmentation may have broad therapeutic implications. • COX-2 is a third endocannabinoid metabolic mechanism. • Substrate-selective COX-2 inhibition increases central endocannabinoid signaling. • Substrate-selective COX-2 inhibition decreases anxiety.
Saved in:
Published in | Trends in pharmacological sciences (Regular ed.) Vol. 35; no. 7; pp. 358 - 367 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.07.2014
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Highlights • Endocannabinoid augmentation may have broad therapeutic implications. • COX-2 is a third endocannabinoid metabolic mechanism. • Substrate-selective COX-2 inhibition increases central endocannabinoid signaling. • Substrate-selective COX-2 inhibition decreases anxiety. |
---|---|
ISSN: | 0165-6147 1873-3735 |
DOI: | 10.1016/j.tips.2014.04.006 |